Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.80
  • Today's Change-0.119 / -0.66%
  • Shares traded328.00
  • 1 Year change-24.70%
  • Beta1.1087
Data delayed at least 15 minutes, as of Jul 11 2025 16:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

  • Revenue in USD (TTM)4.83m
  • Net income in USD53.51m
  • Incorporated2015
  • Employees56.00
  • Location
    PureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttps://puretechhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanrong Biotechnology Corp1.32m-5.08m399.79m3.00------301.79-15.40-15.404.10-11.404.45--11.81441,576.70-1,705.30-----------383.32--0.0315-16.22----91.44---86.62------
Tectonic Therapeutic Inc0.00-58.67m405.57m51.00--1.35-----3.82-3.820.0016.120.00----0.00-33.91---41.26--------------0.0025-------35.40------
CytomX Therapeutics Inc147.56m41.60m409.62m119.005.418.379.462.780.48040.48041.720.31071.04--19.501,239,975.0029.38-15.5894.07-26.48----28.19-50.39----0.00--36.4519.165,700.88---38.41--
Lexicon Pharmaceuticals Inc31.21m-177.30m410.39m103.00--3.34--13.15-0.5144-0.51440.08940.33880.08731.721.27303,038.80-49.60-55.75-61.05-66.3298.0395.36-568.04-1,103.372.22-14.240.4501--2,481.48-37.35-13.15--71.25--
MBX Biosciences Inc0.00-73.47m414.46m43.00--1.76-----3.22-3.220.007.040.00----0.00-45.74---48.16--------------0.00-------90.16------
Nektar Therapeutics87.25m-133.04m418.24m61.00--22.67--4.79-9.52-9.526.241.110.2675--32.731,430,295.00-39.43-35.30-48.62-39.5674.6175.63-147.37-323.39---9.710.00--9.22-3.0056.91---43.84--
Aura Biosciences Inc0.00-94.70m419.48m106.00--2.66-----1.90-1.900.002.550.00----0.00-48.51-36.26-51.38-38.42------------0.00-------13.76---10.82--
Solid Biosciences Inc0.00-139.68m420.13m100.00--1.43-----2.99-2.990.003.800.00----0.00-47.14-47.92-50.84-53.98-------2,151.47----0.0037-------29.87---31.66--
Terns Pharmaceuticals Inc0.00-90.39m425.34m59.00--1.30-----1.09-1.090.003.730.00----0.00-30.84-32.69-31.92-35.03-------33,013.70----0.00------1.50---45.82--
Erasca Inc0.00-157.60m430.60m103.00--1.08-----0.6238-0.62380.001.410.00----0.00-37.47-41.53-40.12-44.78------------0.00-------29.28---36.84--
PureTech Health PLC (ADR)4.83m53.51m431.89m56.007.52--13.7789.452.382.380.1886--0.0075--2.4886,214.294.29-3.274.57-3.83----575.43-253.25----0.052--44.98-13.21181.45-33.81-75.53--
Fulcrum Therapeutics Inc80.00m-510.00k432.37m45.00--1.89417.355.40-0.0289-0.02891.284.230.3367--44.141,777,778.00-0.2146-35.63-0.2235-38.94-----0.6375-314.68----0.00--2,752.05--90.01---20.09--
Tourmaline Bio Inc0.00-82.87m446.21m74.00--1.59-----3.22-3.220.0010.900.00----0.00-25.63-26.41-26.13-27.34------------0.00-------73.80---56.26--
Rezolute Inc0.00-73.00m455.78m59.00--3.85-----1.16-1.160.001.360.00----0.00-80.01-50.36-88.49-53.25------------0.00-------32.19------
Regenxbio Inc156.72m-157.69m456.52m353.00--1.66--2.91-3.11-3.113.085.470.2798--9.21443,960.30-28.16-20.33-34.92-23.7979.1276.64-100.62-82.78---472.540.00---7.6618.7913.81---26.96--
Cullinan Therapeutics Inc0.00-178.74m462.68m111.00--0.8339-----3.09-3.090.009.400.00----0.00-34.74-16.54-36.48-17.34-------1,797.10----0.00-------9.28------
Data as of Jul 11 2025. Currency figures normalised to PureTech Health PLC's reporting currency: US Dollar USD

Institutional shareholders

1.64%Per cent of shares held by top holders
HolderShares% Held
Birch Hill Investment Advisors LLCas of 31 Mar 2025302.00k1.26%
Millennium Management LLCas of 31 Mar 202544.91k0.19%
Pentwater Capital Management LPas of 31 Mar 202533.56k0.14%
Portolan Capital Management LLCas of 31 Mar 202511.89k0.05%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2025100.000.00%
UBS Financial Services, Inc.as of 31 Mar 202520.000.00%
UBS Securities LLCas of 31 Mar 20250.000.00%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.